There is some debate regarding the risk of developing malignancy and progression of
malignancy in patients with psoriasis treated with biologics. The lack of extensive, long‐term …

Simple Summary Psoriasis is a chronic multisystem inflammatory disease associated with a
wide range of comorbidities including cardiovascular disease, hypertension, diabetes …

Background Limited information is available regarding the risk of incident liver disease in
patients with psoriasis receiving systemic therapies. Objectives To describe the liver safety …

BACKGROUND: Although the link between tuberculosis (TB) and biologics use is well
established, the risk of TB among patients with psoriasis exposed to traditional systemic …

Background Psoriasis is a chronic immune‐mediated inflammatory disorder that also occurs
in the setting of human immunodeficiency virus (HIV). Biological therapy has transformed the …

Background Treatment modifications, including dose escalations, dose reductions, switches,
discontinuations and restarts of biologics may be necessary in the management of psoriasis …

Background Methotrexate (MTX) is commonly used in the treatment of patients with
moderate-to-severe psoriasis. Objective We conducted a nationwide population-based …

Objective To describe the use of systemic therapy for psoriasis (biologic and nonbiologic
[classic] drugs) in patients not adequately represented in randomized controlled trials …

Background: Costs and patients' adherence related to biologics are important factors to
consider while making informed decisions regarding therapy with biologics in psoriasis …

Background Anti‐tumour necrosis factor (TNF) and anti‐interleukin (IL)‐12/23 biologics
revolutionized plaque psoriasis treatment by enabling≥ 75% improvement in the Psoriasis …